BMS to acquire precision oncology company Turning Point Therapeutics for $4.1bn

Bristol Myers Squibb (BMS) has agreed to acquire Turning Point Therapeutics, a clinical-stage precision oncology company based in California, for $4.1 billion. Listed on the ... Read More